Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis.

Gatselis NK, Goet JC, Zachou K, Lammers WJ, Janssen HLA, Hirschfield G, Corpechot C, Lindor KD, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Lygoura V, Nevens F, Mason AL, Kowdley KV, Ponsioen CY, Bruns T, Thorburn D, Verhelst X, Harms MH, van Buuren HR, Hansen BE, Dalekos GN; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30888-2. doi: 10.1016/j.cgh.2019.08.013. [Epub ahead of print]

PMID:
31419573
2.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ.

J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11.

PMID:
30980847
3.

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.

Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, Bacon B, Luketic V, Vuppalanchi R, Medendorp S, Dorenbaum A, Kennedy C, Novak P, Gu J, Apostol G, Hirschfield GM.

Hepatol Commun. 2019 Feb 1;3(3):365-381. doi: 10.1002/hep4.1305. eCollection 2019 Mar.

4.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HLA, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028. Epub 2019 Jan 4.

PMID:
30616022
5.

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U.

J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9.

6.

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM.

Hepatol Commun. 2018 Aug 30;2(9):1037-1050. doi: 10.1002/hep4.1209. eCollection 2018 Sep.

7.

A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW.

Hepatol Commun. 2018 Mar 23;2(5):484-491. doi: 10.1002/hep4.1173. eCollection 2018 May.

8.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
9.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

10.

Updated Etiology and Significance of Elevated Bilirubin During Pregnancy: Changes Parallel Shift in Demographics and Vaccination Status.

Duraiswamy S, Sheffield JS, Mcintire D, Leveno K, Mayo MJ.

Dig Dis Sci. 2017 Feb;62(2):517-525. doi: 10.1007/s10620-016-4282-3. Epub 2016 Sep 1.

PMID:
27586034
11.

Predicting Outcomes of Primary Biliary Cholangitis Using the GLOBE Score.

Mayo MJ.

Gastroenterol Hepatol (N Y). 2015 Dec;11(12):842-4. No abstract available.

12.

The Beneficial Effect of Beta-Blockers in Patients With Cirrhosis, Portal Hypertension and Ascites.

Aday AW, Mayo MJ, Elliott A, Rockey DC.

Am J Med Sci. 2016 Feb;351(2):169-76. doi: 10.1016/j.amjms.2015.11.018.

PMID:
26897272
13.

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.

Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group.

Hepatology. 2016 Jul;64(1):189-99. doi: 10.1002/hep.28359. Epub 2016 Jan 14.

PMID:
26597786
14.

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Gastroenterology. 2015 Dec;149(7):1804-1812.e4. doi: 10.1053/j.gastro.2015.07.061. Epub 2015 Aug 7.

PMID:
26261009
15.

Development of a Successful Scholarly Activity and Research Program for Subspecialty Trainees.

Mayo MJ, Rockey DC.

Am J Med Sci. 2015 Sep;350(3):222-7. doi: 10.1097/MAJ.0000000000000489.

PMID:
26002849
16.

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.

Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, Poupon R, Mayo MJ, Burroughs AK, Nevens F, Mason AL, Kowdley KV, Lleo A, Caballeria L, Lindor KD, Hansen BE, Hirschfield GM; Global PBC Study Group.

Gut. 2016 Feb;65(2):321-9. doi: 10.1136/gutjnl-2014-308351. Epub 2015 Jan 7.

PMID:
25567117
17.

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE; Global PBC Study Group.

Gastroenterology. 2014 Dec;147(6):1338-49.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029. Epub 2014 Aug 23.

PMID:
25160979
18.

Does preeclampsia involve the pancreas? A report of original research.

Nelson DB, Duraiswamy S, McIntire DD, Mayo MJ, Leveno KJ.

J Matern Fetal Neonatal Med. 2015 May;28(7):836-8. doi: 10.3109/14767058.2014.935325. Epub 2014 Jul 17.

PMID:
24939629
19.

Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis.

Selmi C, Cavaciocchi F, Lleo A, Cheroni C, De Francesco R, Lombardi SA, De Santis M, Meda F, Raimondo MG, Crotti C, Folci M, Zammataro L, Mayo MJ, Bach N, Shimoda S, Gordon SC, Miozzo M, Invernizzi P, Podda M, Scavelli R, Martin MR, Seldin MF, Lasalle JM, Gershwin ME.

Front Immunol. 2014 Mar 28;5:128. doi: 10.3389/fimmu.2014.00128. eCollection 2014. Erratum in: Front Immunol. 2014;5:371. Seldin, Michael F [added].

20.

Primary biliary cirrhosis in 2014.

Flores A, Mayo MJ.

Curr Opin Gastroenterol. 2014 May;30(3):245-52. doi: 10.1097/MOG.0000000000000058.

PMID:
24671010
21.

Cholestatic liver disease overlap syndromes.

Mayo MJ.

Clin Liver Dis. 2013 May;17(2):243-53. doi: 10.1016/j.cld.2012.12.006. Review.

PMID:
23540500
22.

Management of autoimmune hepatitis.

Mayo MJ.

Curr Opin Gastroenterol. 2011 May;27(3):224-30. doi: 10.1097/MOG.0b013e3283457ce0. Review.

PMID:
21451411
23.

Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people.

Ferucci ED, Hurlburt KJ, Mayo MJ, Livingston S, Deubner H, Gove J, Plotnik J, McMahon BJ.

Can J Gastroenterol. 2011 Jan;25(1):21-7.

24.

Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis.

Mitchell MM, Lleo A, Zammataro L, Mayo MJ, Invernizzi P, Bach N, Shimoda S, Gordon S, Podda M, Gershwin ME, Selmi C, LaSalle JM.

Epigenetics. 2011 Jan;6(1):95-102. doi: 10.4161/epi.6.1.13405. Epub 2011 Jan 1.

25.

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis.

Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ.

Hepatology. 2010 Jul;52(1):349-59. doi: 10.1002/hep.23637. No abstract available.

PMID:
20578151
26.

The 5-D itch scale: a new measure of pruritus.

Elman S, Hynan LS, Gabriel V, Mayo MJ.

Br J Dermatol. 2010 Mar;162(3):587-93. doi: 10.1111/j.1365-2133.2009.09586.x. Epub 2009 Dec 1.

27.

Acute pancreatitis during pregnancy.

Tang SJ, Rodriguez-Frias E, Singh S, Mayo MJ, Jazrawi SF, Sreenarasimhaiah J, Lara LF, Rockey DC.

Clin Gastroenterol Hepatol. 2010 Jan;8(1):85-90. doi: 10.1016/j.cgh.2009.08.035. Epub 2009 Sep 10.

PMID:
19747985
28.

Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production.

Omenetti A, Syn WK, Jung Y, Francis H, Porrello A, Witek RP, Choi SS, Yang L, Mayo MJ, Gershwin ME, Alpini G, Diehl AM.

Hepatology. 2009 Aug;50(2):518-27. doi: 10.1002/hep.23019.

29.

Safety and utility of ERCP during pregnancy.

Tang SJ, Mayo MJ, Rodriguez-Frias E, Armstrong L, Tang L, Sreenarasimhaiah J, Lara LF, Rockey DC.

Gastrointest Endosc. 2009 Mar;69(3 Pt 1):453-61. doi: 10.1016/j.gie.2008.05.024. Epub 2009 Jan 10.

PMID:
19136111
30.

Video games: a route to large-scale STEM education?

Mayo MJ.

Science. 2009 Jan 2;323(5910):79-82. doi: 10.1126/science.1166900.

PMID:
19119223
31.

Hereditary haemorrhagic telangiectasia involving the bone marrow and liver.

Willis J, Mayo MJ, Rogers TE, Chen W.

Br J Haematol. 2009 Apr;145(2):150. doi: 10.1111/j.1365-2141.2008.07452.x. Epub 2008 Nov 20. No abstract available.

PMID:
19036094
32.

Portal hypertension in primary biliary cirrhosis: a potentially reversible harbinger of demise.

Mayo MJ.

Gastroenterology. 2008 Nov;135(5):1450-1. doi: 10.1053/j.gastro.2008.09.041. Epub 2008 Oct 9. No abstract available.

PMID:
18848554
33.

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM.

Hepatology. 2008 Nov;48(5):1549-57. doi: 10.1002/hep.22517.

34.

Natural history of primary biliary cirrhosis.

Mayo MJ.

Clin Liver Dis. 2008 May;12(2):277-88; viii. doi: 10.1016/j.cld.2008.02.012. Review.

PMID:
18456180
35.

Recovery of a Burkholderia thailandensis-like isolate from an Australian water source.

Gee JE, Glass MB, Novak RT, Gal D, Mayo MJ, Steigerwalt AG, Wilkins PP, Currie BJ.

BMC Microbiol. 2008 Apr 2;8:54. doi: 10.1186/1471-2180-8-54.

36.

Tandem repeat regions within the Burkholderia pseudomallei genome and their application for high resolution genotyping.

U'Ren JM, Schupp JM, Pearson T, Hornstra H, Friedman CL, Smith KL, Daugherty RR, Rhoton SD, Leadem B, Georgia S, Cardon M, Huynh LY, DeShazer D, Harvey SP, Robison R, Gal D, Mayo MJ, Wagner D, Currie BJ, Keim P.

BMC Microbiol. 2007 Mar 30;7:23.

37.

Sertraline as a first-line treatment for cholestatic pruritus.

Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ.

Hepatology. 2007 Mar;45(3):666-74.

PMID:
17326161
38.

VNTR analysis of selected outbreaks of Burkholderia pseudomallei in Australia.

Pearson T, U'Ren JM, Schupp JM, Allan GJ, Foster PG, Mayo MJ, Gal D, Choy JL, Daugherty RL, Kachur S, Friedman CL, Leadem B, Georgia S, Hornstra H, Vogler AJ, Wagner DM, Keim P, Currie BJ.

Infect Genet Evol. 2007 Jul;7(4):416-23. Epub 2006 Dec 20.

PMID:
17258514
39.

The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases.

Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, Handem I, Grammer AC, Lipsky PE.

Liver Int. 2006 Mar;26(2):187-96.

PMID:
16448457
40.

Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei.

Novak RT, Glass MB, Gee JE, Gal D, Mayo MJ, Currie BJ, Wilkins PP.

J Clin Microbiol. 2006 Jan;44(1):85-90.

41.

Patients and patience: the pitfalls of primary biliary cirrhosis trials.

Mayo MJ.

Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):552-3. No abstract available.

PMID:
16327817
42.

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.

Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL Jr, Rosoff L Jr, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF.

Hepatology. 2005 Nov;42(5):1184-93.

PMID:
16250039
43.

Burkholderia pseudomallei strain type, based on pulsed-field gel electrophoresis, does not determine disease presentation in melioidosis.

Cheng AC, Day NP, Mayo MJ, Gal D, Currie BJ.

Microbes Infect. 2005 Jan;7(1):104-9. Epub 2004 Nov 18.

PMID:
15716075
44.

Chlorination and pH of drinking water do not correlate with rates of melioidosis in the Northern Territory, Australia.

Cheng AC, Mayo MJ, Gal D, Currie BJ.

Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):511-2.

PMID:
15307412
45.

Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment.

Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME.

Gastroenterology. 2004 Aug;127(2):485-92.

PMID:
15300581
46.

Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis.

Browning J, Combes B, Mayo MJ.

Am J Gastroenterol. 2003 Dec;98(12):2736-41.

PMID:
14687826
47.

Primary biliary cirrhosis: the future.

Mayo MJ.

Clin Liver Dis. 2003 Nov;7(4):957-69. Review.

PMID:
14594140
48.

Extrahepatic manifestations of hepatitis C infection.

Mayo MJ.

Am J Med Sci. 2003 Mar;325(3):135-48. Review.

PMID:
12640289
49.

Exercise-induced weight loss preferentially reduces abdominal fat.

Mayo MJ, Grantham JR, Balasekaran G.

Med Sci Sports Exerc. 2003 Feb;35(2):207-13.

PMID:
12569205
50.

Fatal human melioidosis acquired in a subtropical Australian city.

Munckhof WJ, Mayo MJ, Scott I, Currie BJ.

Am J Trop Med Hyg. 2001 Oct;65(4):325-8.

PMID:
11693877

Supplemental Content

Support Center